Home / Earnings Results / Resmed posts Q2 FY26 earnings growth, lifts dividend

Resmed posts Q2 FY26 earnings growth, lifts dividend

Resmed posts double-digit revenue and profit growth in Q2 FY26, declares dividend, and outlines plans for innovation.

Posted by
Laura Stewart
Author bio Laura Stewart is a Finance Editor at The Motley Fool, where she covers Australian and international equity markets. She joined the company in 2022, following a career transition from legal advisory work in Southeast Asia into the investment industry. Prior to her current editorial role, Laura spent three years as an Equity Analyst and Writer, producing investment research across the ASX, NYSE, and NASDAQ. Her coverage included small-cap growth companies, thematic investment ideas, and high-quality U.S.-listed businesses. Laura holds a Master of Applied Finance and brings additional expertise in accounting, taxation, and estate and wealth planning from her postgraduate studies. She also has a background in law and communications, which supports her analytical and reporting work in financial markets. Outside of work, she enjoys spending time in the Adelaide Hills with her flock of sheep. Education Laura holds a Bachelor of Laws, a Bachelor of Communication (Journalism), and a Bachelor of Commerce with majors in Accounting and Corporate Finance. In 2025, she completed a Master of Applied Finance at the University of Adelaide, receiving postgraduate awards in Accounting Concepts & Methods, Ethical Principles in Accounting & Finance, Real Estate Valuation & Investment, and Tax, Estate & Wealth Planning. Social media LinkedIn FYI – I am taking a break from social media at the moment, so this account isn’t active at the moment, but I will let you know when I rejoin. Favorite investment quote "Compound interest is the eighth wonder of the world. He who understands it, earns it... he who doesn't... pays it." — Albert Einstein
Published
| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resmed CDI (ASX: RMD) share price is in focus after the company reported second quarter revenue up 11% to $1.4 billion and diluted earnings per share rising 15% to $2.68.

a bearded man sits at his desk with hands behind his head and feet on his desk smiling widely while looking at his computer screen which has market data on it, indicating a please share price rise.

Image source: Getty Images

What did Resmed report?

  • Revenue rose 11% year-over-year to $1,422.8 million (up 9% in constant currency).
  • Gross margin increased by 320 basis points to 61.8% (non-GAAP: 62.3%).
  • Income from operations grew 18% to $491.7 million (non-GAAP: up 19%).
  • Net income came in at $392.6 million, up 14% from the prior year period.
  • Diluted earnings per share were $2.68 (non-GAAP: $2.81), up 15% and 16% respectively.
  • Quarterly dividend declared at US$0.60 per share; $88 million returned to shareholders.

What else do investors need to know?

Resmed's second quarter growth was fuelled by robust demand for its sleep and respiratory care devices. Sales improved across most regions, with the US, Canada and Latin America seeing an 11% rise, and Europe and Asia posting 6% constant currency growth (excluding software).

The company reported a $6 million restructuring-related charge, linked to finalising workforce planning initiatives started earlier in the year. Despite slightly higher selling and administration costs, Resmed delivered strong operating cash flow of $340 million and continued its buyback program, repurchasing $175 million in shares.

What's next for Resmed?

Heading into the second half of FY26, Resmed plans to increase investment in digital health solutions and innovation, aiming to expand global access to home-based care. The company is strategically focused on scaling up its AI-enabled technology, following recent FDA clearance for its Smart Comfort device.

Management maintains a goal of sustainable, profitable growth supported by further product development and capital returns, with continued emphasis on research, operational efficiencies, and global market expansion.

Resmed share price snapshot

Over the past 12 months, Resmed shares have declined 10%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 5% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Earnings Results

A casually dressed woman at home on her couch looks at index fund charts on her laptop.
Earnings Results

Pinnacle Investment Management: Profit up 31% on record funds inflow

| James Mickleboro

The company revealed record net inflows of $33.4 billion in FY26.

Read more »

Business people discussing project on digital tablet.
Earnings Results

Charter Hall Social Infrastructure REIT lifts earnings and distributions in FY26

| James Mickleboro

The REIT has provided upbeat guidance for FY27.

Read more »

Smiling man working on his laptop.
Earnings Results

Credit Corp profit jumps 12% with fully franked dividend boost

| James Mickleboro

The debt collector is paying a fully franked final dividend of 45.5 cents per share.

Read more »

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

| Mark Verhoeven

A make-or-break result for Australia's fallen biotech giant.

Read more »

A man in a hard hat and high visibility vest speaks on his mobile phone in front of a digging machine with a heavy dump truck vehicle also visible in the background.
Resources Shares

Antipa Minerals drilling update: Tim's Dome and AL01 drive exploration upside

| Laura Stewart

Antipa Minerals reports new broad gold-copper zones at Tim’s Dome and AL01, strengthening its resource growth strategy.

Read more »

Two boys looking at each other while standing by the start line with two schoolgirls.
Consumer Staples & Discretionary Shares

Briscoe grows sales for third consecutive quarter

| Laura Stewart

Briscoe posts positive sales growth and expects strong profit despite a challenging retail environment.

Read more »

A young woman with glasses holds a pencil to her lips as she is surrounded by the reflection of data as though she is being photographed through a glass screen project with digital data.
Technology Shares

Vista lifts guidance as cloud and market share growth accelerates

| Laura Stewart

Vista upgraded its FY26 revenue guidance after strong H1 growth in cloud and payments, with market share at 48% and…

Read more »

Woman presenting financial report on large screen in conference room.
Earnings Results

Your August ASX reporting season calendar: 5 results that matter most

| Mark Verhoeven

Five dates to circle this earnings season.

Read more »